IL182693A0 - Methods of preparing indazole compounds - Google Patents

Methods of preparing indazole compounds

Info

Publication number
IL182693A0
IL182693A0 IL182693A IL18269307A IL182693A0 IL 182693 A0 IL182693 A0 IL 182693A0 IL 182693 A IL182693 A IL 182693A IL 18269307 A IL18269307 A IL 18269307A IL 182693 A0 IL182693 A0 IL 182693A0
Authority
IL
Israel
Prior art keywords
methods
indazole compounds
preparing indazole
preparing
compounds
Prior art date
Application number
IL182693A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL182693A0 publication Critical patent/IL182693A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL182693A 2004-11-02 2007-04-19 Methods of preparing indazole compounds IL182693A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US71707105P 2005-09-14 2005-09-14
PCT/IB2005/003297 WO2006048744A1 (en) 2004-11-02 2005-10-21 Methods of preparing indazole compounds

Publications (1)

Publication Number Publication Date
IL182693A0 true IL182693A0 (en) 2007-09-20

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182693A IL182693A0 (en) 2004-11-02 2007-04-19 Methods of preparing indazole compounds

Country Status (14)

Country Link
US (1) US7232910B2 (OSRAM)
EP (1) EP1809621A1 (OSRAM)
JP (1) JP2008518900A (OSRAM)
KR (1) KR20070058690A (OSRAM)
AR (1) AR051754A1 (OSRAM)
AU (1) AU2005300310A1 (OSRAM)
BR (1) BRPI0518203A2 (OSRAM)
CA (1) CA2586174A1 (OSRAM)
IL (1) IL182693A0 (OSRAM)
MX (1) MX2007005291A (OSRAM)
NO (1) NO20071619L (OSRAM)
RU (1) RU2007116107A (OSRAM)
TW (1) TWI294421B (OSRAM)
WO (1) WO2006048744A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101237588B1 (ko) 2007-04-05 2013-02-27 화이자 프로덕츠 인코포레이티드 포유동물에서의 비정상적인 세포 생장의 치료에 적합한 6-〔2-(메틸카바모일)페닐설파닐〕-3-ｅ-〔2-(피리딘-2-일)에테닐〕인다졸의 결정질 다형체
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
CA2749012C (en) * 2009-01-08 2017-01-31 Merck Patent Gmbh Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
KR20140069297A (ko) 2011-09-30 2014-06-09 화이자 인코포레이티드 N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
BR112014011453A2 (pt) 2011-11-11 2017-05-02 Pfizer n-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida para o tratamento de leucemia mielógena crônica
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
ES2768678T3 (es) * 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
CN118286440A (zh) 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
WO2015152117A1 (ja) * 2014-03-31 2015-10-08 千寿製薬株式会社 アルキニルインダゾール誘導体及びその用途
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
KR102712880B1 (ko) 2015-06-16 2024-10-02 메르크 파텐트 게엠베하 Pd-l1 길항제 조합 치료
MX2019003755A (es) 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
JP7200399B2 (ja) * 2019-04-18 2023-01-06 シントン・ビー．ブイ． アキシチニブの製造方法、中間体２－（（３－ヨード－１ｈ－インダゾール－６－イル）チオ）－ｎ－メチルベンズアミドの精製方法、アキシチニブ塩酸塩によるアキシチニブの精製方法、アキシチニブ塩酸塩の固体形態
MX2024010773A (es) 2022-03-03 2024-09-10 Pfizer Anticuerpos multiespecificos y usos de estos.
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2517517C (en) * 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2006522087A (ja) 2003-04-03 2006-09-28 ファイザー・インク Ａｇ０１３７３６を含んでなる剤形
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Also Published As

Publication number Publication date
TW200621721A (en) 2006-07-01
CA2586174A1 (en) 2006-05-11
RU2007116107A (ru) 2008-11-10
US20060094881A1 (en) 2006-05-04
JP2008518900A (ja) 2008-06-05
NO20071619L (no) 2007-04-25
US7232910B2 (en) 2007-06-19
KR20070058690A (ko) 2007-06-08
TWI294421B (en) 2008-03-11
AU2005300310A1 (en) 2006-05-11
AR051754A1 (es) 2007-02-07
BRPI0518203A2 (pt) 2009-03-10
EP1809621A1 (en) 2007-07-25
MX2007005291A (es) 2007-07-19
WO2006048744A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
IL182693A0 (en) Methods of preparing indazole compounds
ZA200702977B (en) Methods of preparing indazole compounds
IL182096A0 (en) Methods for preparing indazole compounds
ZA200704350B (en) Methods for preparing indazole compounds
IL191990A0 (en) Methods of using cd40 binding agents
TWI340137B (en) Preparation process
IL183091A0 (en) Method for preparing n-phenylpyrazole-1-carboxyamides
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
IL183176A0 (en) Methods for the preparation of sevoflurane
ZA200704535B (en) Process for preparing rosuvastatin
IL185757A0 (en) Methods of decreasing calcifcation
IL182421A0 (en) Process for the preparation of pyrazoles
GB2436262B (en) Process for the preparation of pantoprazole sodium
IL178071A0 (en) Process for preparing pyridazinone compounds
IL177315A0 (en) Process for the preparation of substituted triazole compounds
EP1893625A4 (en) PROCESS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES
ZA200703495B (en) Process for the preparation of irbesartan hydrochloride
IL208214A0 (en) Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
EP1964538A4 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
EP1917231A4 (en) PROCESS FOR THE PRODUCTION OF BROMOPICRIN
EP2147916A4 (en) PROCESS FOR THE PREPARATION OF SYNTHETIC TAXANES
HUP0401379A3 (en) Process for the preparation of risperidon
IL183804A0 (en) Process for preparing substituted 2-alkoxycarbonyl-3-aminothiophenes
PL378094A1 (pl) Sposób wytwarzania aldehydów
IL183605A0 (en) Methods for preparing indazole compounds